BAY 509062

Drug Profile

BAY 509062

Alternative Names: 17 beta HSD inhibitor - Bayer; 17 beta Hydroxysteroid Dehydrogenase inhibitor - Bayer; Estradiol 17 beta dehydrogenase inhibitor - Bayer

Latest Information Update: 11 Dec 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Class Osteoporosis therapies
  • Mechanism of Action Estradiol dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Osteoporosis

Most Recent Events

  • 11 Dec 2003 No development reported - Preclinical for Osteoporosis in Germany (unspecified route)
  • 28 Sep 2001 BAY 509062 is available for licensing
  • 30 Mar 2001 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top